Table 3.

Regression analysis of factors affecting odds of response and hazards of relapse/death

Logistic regression analysis of factor affecting ORR
UVAMVA
VariableOR95% CIP valueVariableOR95% CIP value
SFmut 0.9 0.66-1.24 .51 SFmut 0.91 0.53-1.32 .63 
Age ≥ 60 years 0.63 0.44-0.87 .006 Age ≥ 60 1.03 0.65-1.63 .89 
De novo AML 2.95 2.19-3.98 <.0001 De novo AML 1.89 1.36-2.64 .0002 
ELN AR 0.26 0.18-0.36 <.0001 ELN Adverse 0.6 0.36-1.01 .05 
LI therapy 0.51 0.36-0.69 <.0001 LI therapy 0.58 0.37-0.92 .02 
Venetoclax 2.14 1.60-2.87 <.0001 Venetoclax 2.45 1.77-3.41 <.0001 
Logistic regression analysis of factor affecting ORR
UVAMVA
VariableOR95% CIP valueVariableOR95% CIP value
SFmut 0.9 0.66-1.24 .51 SFmut 0.91 0.53-1.32 .63 
Age ≥ 60 years 0.63 0.44-0.87 .006 Age ≥ 60 1.03 0.65-1.63 .89 
De novo AML 2.95 2.19-3.98 <.0001 De novo AML 1.89 1.36-2.64 .0002 
ELN AR 0.26 0.18-0.36 <.0001 ELN Adverse 0.6 0.36-1.01 .05 
LI therapy 0.51 0.36-0.69 <.0001 LI therapy 0.58 0.37-0.92 .02 
Venetoclax 2.14 1.60-2.87 <.0001 Venetoclax 2.45 1.77-3.41 <.0001 
Cox regression analysis for hazards of relapse in death in older patients treated with LI therapy
RFS
UVAMVA
VariableHR95% CIP valueVariableHR95% CIP value
SFmut 0.88 0.71-1.14 .35 SFmut 0.75 0.59-0.96 .022 
De novo AML 0.66 0.53-0.83 <.0001 De novo AML 0.69 0.54-0.87 .002 
ELN AR 1.72 1.36-2.19 <.0001 ELN AR 1.65 1.28-2.12 <.0001 
Venetoclax 0.59 0.46-0.77 <.0001 Venetoclax 0.73 0.57-0.95 .02 
SCT 0.32 0.22-0.45 <.0001 SCT 0.31 0.22-0.44 <.001 
Cox regression analysis for hazards of relapse in death in older patients treated with LI therapy
RFS
UVAMVA
VariableHR95% CIP valueVariableHR95% CIP value
SFmut 0.88 0.71-1.14 .35 SFmut 0.75 0.59-0.96 .022 
De novo AML 0.66 0.53-0.83 <.0001 De novo AML 0.69 0.54-0.87 .002 
ELN AR 1.72 1.36-2.19 <.0001 ELN AR 1.65 1.28-2.12 <.0001 
Venetoclax 0.59 0.46-0.77 <.0001 Venetoclax 0.73 0.57-0.95 .02 
SCT 0.32 0.22-0.45 <.0001 SCT 0.31 0.22-0.44 <.001 
OS
SFmut 0.85 0.69-1.05 .14 SFmut 0.74 0.59-0.91 .004 
De novo AML 0.55 0.45-0.68 <.0001 De novo AML 0.60 0.49-0.75 <.0001 
ELN AR 2.01 1.59-2.54 <.0001 ELN AR 1.69 1.33-2.15 .0001 
Venetoclax 0.59 0.48-0.73 <.0001 Venetoclax 0.76 0.62-0.94 .011 
SCT 0.25 0.17-0.38 <.0001 SCT 0.27 0.18-0.41 <.0001 
OS
SFmut 0.85 0.69-1.05 .14 SFmut 0.74 0.59-0.91 .004 
De novo AML 0.55 0.45-0.68 <.0001 De novo AML 0.60 0.49-0.75 <.0001 
ELN AR 2.01 1.59-2.54 <.0001 ELN AR 1.69 1.33-2.15 .0001 
Venetoclax 0.59 0.48-0.73 <.0001 Venetoclax 0.76 0.62-0.94 .011 
SCT 0.25 0.17-0.38 <.0001 SCT 0.27 0.18-0.41 <.0001 
Cox regression analysis for hazards of relapse in death in younger patients treated with INT therapy
RFS
UVAMVA
SFmut 1.45 0.82-2.57 .2 SFmut 0.95 0.53-1.69 .85 
De novo 0.95 0.58-1.54 .83     
ELN AR 1.6 1.06-2.43 .03 ELN AR 2.52 1.61-3.92 <.0001 
Venetoclax 1.07 0.70-1.65 .75     
SCT 0.183 0.12-0.29 <.0001 SCT 0.15 0.09-0.24 <.0001 
Cox regression analysis for hazards of relapse in death in younger patients treated with INT therapy
RFS
UVAMVA
SFmut 1.45 0.82-2.57 .2 SFmut 0.95 0.53-1.69 .85 
De novo 0.95 0.58-1.54 .83     
ELN AR 1.6 1.06-2.43 .03 ELN AR 2.52 1.61-3.92 <.0001 
Venetoclax 1.07 0.70-1.65 .75     
SCT 0.183 0.12-0.29 <.0001 SCT 0.15 0.09-0.24 <.0001 
OS
SFmut 0.94 0.49-1.83 .86 SFmut 0.63 0.32-1.24 .44 
De novo AML 0.55 0.35-0.86 .009 De novo AML 0.54 0.33-0.87 .18 
ELN AR 2.92 1.86-4.58 <.0001 ELN AR 2.94 1.82-4.74 <.0001 
Venetoclax 1.03 0.67-1.60 .89     
SCT 0.26 0.16-0.42 <.0001 SCT 0.21 0.13-0.35 <.0001 
OS
SFmut 0.94 0.49-1.83 .86 SFmut 0.63 0.32-1.24 .44 
De novo AML 0.55 0.35-0.86 .009 De novo AML 0.54 0.33-0.87 .18 
ELN AR 2.92 1.86-4.58 <.0001 ELN AR 2.94 1.82-4.74 <.0001 
Venetoclax 1.03 0.67-1.60 .89     
SCT 0.26 0.16-0.42 <.0001 SCT 0.21 0.13-0.35 <.0001 

Only factors significant on UVA at P < .05 or relevant to the analysis (ie, SF mutations) were used in MVA.

ELN AR, ELN 2017 AR; OR, odds ratio; SCT, allogeneic SCT.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal